

1997

1. Koenig W, Sund M, Döring A, Ernst E (1997). Leisure-time physical activity but not work-related physical activity is associated with decreased plasma viscosity. Results from a large population sample. *Circulation* 95:335-41
2. Koenig W, Höher M (1997). Felodipine and amlodipine in stable angina pectoris: Results of a randomized double-blind cross-over trial. *J Cardiovasc Pharmacol* 29:520-4
3. Koenig W, Hoffmeister A, Hombach V (1997). Hyperfibrinogenemia and cardiovascular risk: possible strategies for intervention. *Fibrinolysis & Proteolysis Suppl* 1:41-6
4. Koenig W, Löwel H, Lewis M, Filipiak, B Hörmann A (1997). Long-term survival after myocardial infarction: Relationship with thrombolysis and discharge medication. Reply to Prof Goldbourt. Letter to the editor. *Eur Heart J* 18:169
5. Koenig W, Ernst E, Sund M, Döring A (1997). Leisure time physical activity and plasma viscosity. Reply to Dr. Reinhardt. Letter to the editor. *Circulation* 96: 3784
6. Peters A, Döring A, Wichmann HE, Koenig W (1997). Increased plasma viscosity during the 1985 air pollution episode: A link to mortality? *Lancet* 349:1582-87
7. Fröhlich M, Sund M, Russ S, Hoffmeister A, Fischer HG, Hombach V, Koenig W (1997). Seasonal variations of rheological and hemostatic parameters, and acute phase reactants in young, healthy subjects. *Arterioscler Thromb Vasc Biol* 17:2692-7
8. Ernst E, Koenig W (1997). Fibrinogen and cardiovascular risk. *Vasc Med* 2:115-25
9. Ernst E, Koenig W (1997). Therapie der chronischen Herzinsuffizienz mit Betarezeptorenblockern: Von der Kontraindikation zur Indikation? *Perfusion* 10:96-100
10. Hombach V, Kochs M, Höher M, Osterhues HH, Koenig W, Weismüller P (1997). Alternativen zur Ballonangioplastie. Radiofrequenzangioplastie, direktionale koronare Atherektomie, Hochfrequenz-Rotationsangioplastie und koronare Extraktions-Atherektomie. *Z Kardiol* 38:11-9

1998

11. Koenig W, Sund M, Filipiak B, Döring A, Löwel H, Ernst E (1998). Plasma viscosity and the risk of coronary heart disease. Results from the MONICA-Augsburg Cohort Study 1984 -1992. *Arterioscler Thromb Vasc Biol* 18:768-72

12. Koenig W (1998) . Referenzwerte in der Langzeitblutdruckmessung. Dtsch Med Wochenschr 123:1125
13. Koenig W (1998). Haemostatic risk factors for cardiovascular diseases. Eur Heart J 19(Suppl C):C39-43
14. Koenig W (1998). Epidemiologie der koronaren Herzkrankheit. In: Leschke M, Schöbel C, Strauer BE Hrsg. Chronische Myokardischämie. Z Kardiol 87(Suppl 2):3-7
15. Gehring J, Koenig W, Donner M, Wex R, Klein G (1998). The diagnostic value of signal-averaged stress cardiokymography compared with exercise electrocardiography. J Noninvasive Cardiol 2:32-41
16. Voisard R, Oßwald M, Baur R, Jacob U, Susa M, Mattfeldt T, Hemmer W, Hannekum A, Koenig W, Hombach V (1998). Expression of intercellular adhesion molecule-1 in human coronary endothelial and smooth muscle cells after stimulation with tumor necrosis factor- α . Coronary Artery Disease 9:737-45
17. Haug C, Koenig W, Höher M, Kochs M, Hombach V, Grünert A, Osterhues HH (1998). Direct enzyme immunometric measurement of plasma big endothelin-1 concentrations and correlation with indicators of left ventricular function. Clin Chem 44:239-43
18. Fröhlich M, Schunkert H, Hense HW, Tropitzsch A, Hendricks P, Döring A, Riegger GAJ, Koenig W (1998). Effects of hormone replacement therapies on fibrinogen and plasma viscosity in postmenopausal women. Br J Haematol 100:577-81
19. Grossmann G, Stein M, Kochs M, Höher M, Koenig W, Hombach V, Giesler M (1998). Comparison of the proximal flow convergence method and the jet area method for the assessment of the severity of tricuspid regurgitation. Eur Heart J 19:652-9
20. Schüppel R, Büchele G, Batz L, Koenig W (1998). Sex differences in selection of pacemakers: retrospective observational study. Br Med J 316:1492-4
21. Staels B, Koenig W, Habib A, Merval R, Lebret M, Pineda-Torra I, Delerive Ph, Fadel A, Chinetti G, Fruchart J-Ch, Najib J, Maclouf J, Tedgui A (1998). Activation of human aortic smooth-muscle cells is inhibited by PPAR α but not by PPAR γ activators. Nature 393:790-3
22. Torzewski J, Torzewski M, Bowyer DE, Fröhlich M, Koenig W, Waltenberger J, Fitzsimmons C, Hombach V (1998) . C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries. Arterioscler Thromb Vasc Biol 18:1386-92
23. Hoffmeister HM, Koenig W (1998). Fibrinogen - just a protein? A Meeting Report. Thrombosis and Thrombolysis

24. Ernst E, Koenig W (1998). Fibrinogen: risk factor or risk marker? In: Gotto AM, Jr et al (eds) Multiple Risk Factors in Cardiovascular Disease: Strategies of prevention of coronary heart disease, cardiac failure, and stroke. Proceedings of a Symposium. Kluwer Academic Publishers and Fondazioni Giovanni Lorenzini: 75-84
25. Fischer HG, Koenig W (1998). Physical activity and coronary heart disease. *Cardiologia* 43:1027-35

1999

26. Koenig W, Sund M, Fröhlich M, Fischer H-G, Löwel H, Döring A, Hutchinson WL, Pepys MB (1999). C-reactive protein, a sensitive marker of systemic inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men. Results from the MONICA-Augsburg cohort study 1984-92. *Circulation* 99:237-42
27. Koenig W, Rothenbacher D, Hoffmeister A, Miller M, Bode G, Adler G, Hombach V, März W, Pepys MB, Brenner H (1999). Infection with *Helicobacter pylori* is not a major independent risk factor for stable coronary heart disease. Lack of a role of cytotoxin-associated protein A-positive strains and absence of a systemic inflammatory response. *Circulation* 100:2326-31
28. Koenig W (1999). Fibrinogen and coronary risk: in Fuster V, Hrsg.: Current Science Inc. Philadelphia, USA. *Current Review of Cardiology* I:112-8
29. Koenig W (1999). Atherosclerosis involves more than just lipids: Focus on inflammation. *Eur Heart J* 1(Suppl T):T19-26
30. Koenig W, Wanner C (1999). C-reactive protein and coronary artery disease - what is the link? Editorial. *Nephrol Dial Transplant* 14:2798-800
31. Fröhlich M, Döring A, Hutchinson WL, Imhof A, Fischer HG, Pepys MB, Koenig W (1999). Association of oral contraceptive use with markers of systemic inflammation. *Fibrinolysis & Proteolysis* 13:239-44
32. Löwel H, Stieber J, Koenig W, Thorand B, Hörmann A, Gostomzyk J, Keil U (1999). Das Diabetes-bedingte Herzinfarkttrisiko in einer süddeutschen Bevölkerung: Ergebnisse der MONICA-Augsburg-Studien 1985-1994. *Diab Stoffw* 8:11-21
33. Rothenbacher D, Hoffmeister A, Bode G, Wanner P, Koenig W, Brenner H (1999). Cytomegalovirus infection and coronary heart disease: Results of a case-control study from Germany. *J Infect Dis*, 179:690-2
34. Hoffmeister A, Hetzel J, Sander S, Kron M, Kochs M, Hombach V, Koenig W (1999). Markers of inflammation and blood rheology in relation to haemodynamic findings in chronic congestive heart failure. *Eur J Heart Failure* 1:293-5

35. Peters A, Perz S, Döring A, Stieber J, Koenig W, Wichmann HE (1999). Increases in heart rate during an air pollution episode. *Am J Epidemiol* 150:1094-8
36. Brenner H, Berg G, Fröhlich M, Boeing H, Koenig W (1999). Chronic infection with *Helicobacter pylori* does not provoke major systemic inflammation among healthy adults. Results from a large population-based study. *Atherosclerosis* 147:399-403

2000

37. Koenig W, Sund M, Döring A, Löwel H, Ernst E (2000). Plasma viscosity: An independent predictor of all-cause mortality. Results from the MONICA-Augsburg Cohort Study 1984-1992. *Brit J Haematol* 109:453-8
38. Koenig W (2000). Efficacy, tolerability, and safety of the fixed combination of candesartan cilexetil and hydrochlorothiazide with losartan and hydrochlorothiazide in patients with moderate to severe hypertension. A randomized double-blind multicentre trial. *Clin Drug Invest* 19:239-46
39. Koenig W, Ernst E (2000). Exercise and thrombosis. *Coron Artery Dis* 11:123-7
40. Koenig W (2000). Epidemiology and genetics of thromboembolic diseases. *Bulletin of the IDF* 353:60-4
41. Koenig W, Wanner C (2000). C-reactive protein and cardiovascular disease: linked by complement? *Nephrol Dial Transplant* 15:1709-10
42. Koenig W (2000). Heart disease and the inflammatory response. *BMJ* 321:187-8
43. Peters A, Perz S, Döring A, Stieber J, Koenig W, Wichmann HE (2000). Activation of the autonomic nervous system and blood coagulation in association with an air pollution episode. *Inhalation Toxicology* 12 (Suppl 2):51-61
44. Löwel H, Koenig W, Engel S, Hörmann A, Keil U (2000). The impact of diabetes mellitus on survival after myocardial infarction: can it be modified by drug treatment? Results of a population-based myocardial infarction register follow-up study. *Diabetologia* 43:218-26
45. Hoffmeister A, Rothenbacher D, Wanner P, Bode G, Persson K, Brenner H, Hombach V, Koenig W (2000). Seropositivity to chlamydial lipopolysaccharide and *Chlamydia pneumoniae*, systemic inflammation and stable coronary artery disease. Negative results of a case-control study. *J Am Coll Cardiol* 35:112-8
46. Hutchinson WL, Koenig W, Fröhlich M, Sund M, Lowe GDO, Pepys MB (2000). Immunoradiometric assay of circulating C-reactive protein: Age related values in the adult general population. *Clin Chem* 46:934-8

47. Torzewski M, Rist C, Mortensen RF, Zwaka ThP, Bienek M, Waltenberger J, Koenig W, Schmitz G, Hombach V, Torzewski J (2000) . C-reactive protein in the arterial intima. Role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis. *Arterioscler Thromb Vasc Biol* 20:2094-9
48. Schunkert H, Koenig W, Bröckel U, Muscholl MW, Döring A, Riegger GAJ, Hense HW (2000) . Haematocrit profoundly affects left ventricular diastolic filling as assessed by Doppler echocardiography. *J Hypertens* 18:1483-9
49. Fröhlich M, Imhof A, Berg G, Hutchinson WL, Pepys MB, Boeing H, Brenner H, Koenig W (2000) . Association between C-reactive protein and features of the metabolic syndrome: a population-based study. *Diabetes Care* 23:1835-9

2001

50. Koenig W, Rothenbacher D, Hoffmeister A, Griesshammer M, Brenner H (2001). Plasma fibrin D-dimer levels and risk of stable coronary artery disease. *Arterioscler Thromb Vasc Biol* 21:1701-5
51. Koenig W (2001). Efficacy and tolerability of 100 mg and 200 mg metoprolol once daily in two different extended-release preparations in patients with mild to moderate essential hypertension. A randomized double-blind multicentre trial. *Clin Drug Invest* 19:239-46
52. Koenig W, Torzewski J (2001). C-reactive protein and atherosclerosis: Quo vadis? *Ital Heart J* 2:801-3
53. Koenig W (2001). Inflammation and coronary heart disease: An overview. *Cardiology in Review* 9:31-5
54. Koenig W, Löwel H (2001). Cardiovascular disease in women. Epidemiology and problems in management. *Proceedings Femmes et Nutrition. Actualites et implications pratique* 73-86
55. Koenig W (2001). C-reactive protein: Risk assessment in primary prevention. *Ital Heart J* 2:157-63
56. Koenig W (2001). Antibiotikatherapie bei Herzinfarkt? *Dtsch Med Wochenschr* 125;188-9
57. Koenig W (2001). C-reactive protein and cardiovascular risk: Has the time come for screening the general population? Editorial. *Clin Chem*, 47: 9-10
58. Koenig W (2001). Neue Rolle für Entzündungsmarker. CRP und Fibrinogen in der Atherosklerose-Prävention. *Roche-Dialog* 2: 28-30
59. Koenig W, Marx N (2001). Atherothrombotische Komplikationen. Warum Diabetiker besonders stark gefährdet sind. *CARDIOVASC* 1 12-14

60. Hombach V, Koenig W, Kochs M (2001). Akuter Herzinfarkt: Epidemiologie und Prähospitalphase. Internist 42 : 649-58
61. Bode G, Hoffmeister H, Koenig W, Brenner H, Rothenbacher D (2001). Characteristics of differences in *Helicobacter pylori* serology and ¹³C-urea breath testing in an asymptomatic sample of blood donors. Scand J Clin Lab Invest 61:603-8
62. Voisard R, Huber N, Baur R, Susa M, Ickrath O, Both A, Koenig W, Hombach V (2001). Different effects of antisense RelA p65 and NF-kappaB1 p50 oligonucleotides on the NF-kappaB mediated expression of ICAM-1 in human coronary endothelium and smooth muscle cells. BMC Mol Biol 2:7
63. Hoffmeister A, Rothenbacher D, Bätzner U, Fröhlich M, Brenner H, Hombach V, Koenig W (2001). Role of novel markers of inflammation in patients with stable coronary heart disease. Am J Cardiol 87:262-6
64. Brenner H, Bode G, Adler G, Hoffmeister A, Koenig W, Rothenbacher D (2001). Alcohol as a gastric disinfectant? The complex relation between alcohol consumption and current *Helicobacter pylori* infection. Epidemiology 12:209-14
65. Hoffmeister A, Rothenbacher D, Bode G, Persson K, März W, Nauck MA, Brenner H, Hombach V, Koenig W (2001). Current infection with *Helicobacter pylori* but not seropositivity to *Chlamydia pneumoniae* or cytomegalovirus is associated with an atherogenic lipid profile. Arterioscler Thromb Vasc Biol 21:427-32
66. Imhof A, Fröhlich M, Brenner H, Boeing H, Pepys MB, Koenig W (2001) . Effect of alcohol consumption on systemic markers of inflammation. Lancet 357:763-7
67. Voisard R, Fischer R, Oßwald M, Voglic S, Baur R, Susa M, Koenig W, Hombach V (2001). Aspirin (5mM) inhibits leukocyte attack and triggered reactive proliferation of smooth muscle cells in a 3D human coronary in vitro model. Circulation 103:1688-94
68. Ibald-Mulli A, Stieber J, Wichmann HE, Koenig W, Peters A (2001). Effects of air pollution on blood pressure: a population based approach. Am J Publ Health 91:571-7
69. Rothenbacher D, Hoffmeister A, Bode G, Miller M, Koenig W, Brenner H (2001). *Helicobacter pylori* heat shock protein 60 and risk of coronary heart disease: a case-control study with focus on markers of systemic inflammation and lipids. Atherosclerosis 156:193-9
70. Peters A, Fröhlich M, Döring A, Immervoll Th, Wichmann HE, Hutchinson WL, Pepys MB, Koenig W (2001). Particulate air pollution is associated with an acute phase response in men. Results from the MONICA-Augsburg Study. Eur Heart J 22:1198-1204

71. Brenner H, Rothenbacher D, Bode G, März W, Hoffmeister A, Koenig W (2001). Coronary heart disease risk reduction in a predominantly beer-drinking population. *Epidemiology* 12: 390-5
72. Voisard R, Voglic S, Baur R, Susa M, Koenig W, Hombach V (2001). Leukocyte attack in a 3D human coronary in-vitro model. *Coron Artery Dis*, 12:401-11
73. Imhof A, Koenig W (2001). Exercise and thrombosis. *Cardiology Clinics*. G. Balady, Hrsg. WB Saunders, Philadelphia: 389-400
74. Haase KK, Koenig W (2001). Stellenwert der GP IIb/IIIa Rezeptor Antagonisten bei Patienten mit akutem Koronarsyndrom. *Perfusion* 14:56-60

2002

75. Koenig W, Khuseyinova N, Hoffmann MM, März W, Fröhlich M, Hoffmeister A, Brenner H, Rothenbacher D (2002). CD14 C(-260)→T polymorphism, plasma levels of the soluble endotoxin receptor CD14, their association with chronic infections and risk of stable coronary artery disease: Results of a large case-control study. *J Am Coll Cardiol* 40:34-42
76. Koenig W, Rosenson RS (2002). Emerging risk factors: Acute phase reactants, in: Lowe GDO, Danesh J, guest editors: Risk factors for coronary disease. *Sem Vasc Med* 417-28
77. Koenig W (2002). Diabetes mellitus und koronare Herzkrankheit: Epidemiologische Daten. *J Kardiologie* 9:548-50
78. Koenig W, Pepys MB (2002). CRP risk prediction: low specificity, high sensitivity. Editorial. *Ann Intern Med* 136:550-2
79. Koenig W (2002). Atherosklerose – Immunantwort an die falsche Adresse? Editorial. *Dtsch Med Wochenschr* 127:369
80. Koenig W (2002). Is measuring endothelial function a good idea for the prediction of coronary heart disease complications? Editorial. *Eur Heart J* 23: 1728-30
81. Koenig W (2002). Therapie der arteriellen Hypertonie – was haben wir erreicht? Editorial. *Perfusion* 5:202
82. Koenig W (2002). Insulin resistance, heart disease and inflammation: Identifying the `at risk` patient: the earlier the better? The role of inflammatory markers. *Int J Clin Pract* 132 (Suppl):23-30
83. Störk T, Gareis R, Müller R, Hämmerle M, Müller-Bardorff M, Braun R, Fröhlich E, Koenig W, Möckel M (2002). Suspected acute coronary syndrome in patients without ST-segment elevation: rule-out infarction, value of clinical decision-making and non-coronary diagnoses. *Dtsch Med Wochenschr* 127:260-5

84. Fröhlich M, Sund M, Thorand B, Hutchinson WL, Pepys MB, Koenig W (2002). Lack of seasonal variation in C-reactive protein. *Clin Chem* 48:575-7
85. Marx N, Kehrle B, Kohlhammer K, Grüb M, Koenig W, Hombach V, Libby P, Plutzky J (2002). PPAR activators as anti-inflammatory mediators in human T-lymphocytes: Implications for atherosclerosis and transplantation-associated arteriosclerosis *Circ Research*, 90:703-10
86. Rothenbacher D, Fischer HG, Hoffmeister A, Hoffmann MM, März W, Bode G, Rosenthal J, Koenig W, Brenner H (2002). Homocysteine and methylenetetrahydrofolate reductase genotype: association with risk of coronary heart disease and relation to inflammatory, hemostatic, and lipid parameters. *Atherosclerosis* 162:193-200
87. Müller S, Martin S, Koenig W, Hanifi-Moghaddam P, Rathmann W, Haastert B, Giani G, Illig Th, Thorand B, Kolb H (2002). Impaired glucose tolerance is associated with increased serum levels of interleukin-6 and acute phase proteins indicating systemic inflammation. *Diabetologia* 45:805-12
88. Löwel H, Meisinger C, Heier M, Hörmann A, Kuch B, Gostomzyk J, Koenig W (2002). Geschlechtsspezifische Trends von plötzlichem Herztod und akutem Herzinfarkt: Ergebnisse des bevölkerungsbasierten Augsburger Herzinfarkt-Registers 1985-1998. *Dtsch Med Wochenschr* 127:2311-6
89. Hoffmeister A, Rothenbacher D, Khuseyinova N, Brenner H, Koenig W (2002). Plasminogen levels and risk of coronary artery disease – A case-control study. *Am J Cardiol* 90:1168-70
90. Rosenson RS, Koenig W (2002). High-sensitivity CRP and cardiovascular risk in CHD patients. *Curr Opin Cardiol* 17:325-31
91. Süsselbeck T, Borggrefe M, Koenig W, Haase KK (2002). Interventionelle Therapie bei Patienten mit akutem Myokardinfarkt. *Perfusion* 15:239-46
92. Poerner TC, Sueselbeck T, Baumbach A, Oberhoff M, Herdeg C, Wnendt S, Borggrefe M, Koenig W, Haase KK (2002). Koronare Stents: Aktuelle Entwicklungen und Perspektiven. *Perfusion* 15:434-48

2003

93. Koenig W, Sund M, Fröhlich M, Löwel H, Hutchinson WL, Pepys MB (2003). Refinement of the association of serum C-reactive protein concentration and coronary heart disease risk by correction for within-subject variation over time. Results from the MONICA-Augsburg studies 1984 and 1987. *Am J Epidemiol* 158:357-64
94. Koenig W, Hoffmeister A, Khuseyinova N, Imhof A (2003). Atherosklerose als inflammatorischer Prozess: C-reaktives Protein und koronares Risiko. *Dtsch Ärztebl* 100:A117-26
95. Koenig W (2003). Fibrin(ogen) in cardiovascular disease - an update. *Thromb Haemost* 89:601-9

96. Koenig W (2003). C-reactive protein and cardiovascular risk: an update on what is going on in cardiology. *Nephrol Dial Transplant* 18:1039-41
97. Koenig W. (2003). Update on C-reactive protein as a risk marker in cardiovascular disease. *Kidney Int* 84(Suppl):S58-61
98. Koenig W (2003). Global cardiovascular risk assessment: improving strategies in patients at intermediate risk. *Int J Clin Pract* 137(Suppl):34-43
99. Koenig W (2003). Besitzen Patienten mit rheumatoider Arthritis ein erhöhtes kardiovaskuläres Risiko? Kommentar. *Dtsch Med Wochenschr* 128:911
100. Rosenson RS, Koenig W (2003). Utility of inflammatory markers in the management of coronary artery disease. *Am J Cardiol* 92 (Suppl):10i-18i
101. Fröhlich M, Mühlberger N, Hanke H, Imhof A, Döring A, Pepys MB, Koenig W (2003). Markers of inflammation in women on different hormone replacement therapies. *Ann Med* 35:353-61
102. Thorand B, Löwel H, Schneider A, Kolb H, Meisinger Ch, Fröhlich M, Koenig W (2003). C-reactive protein as a predictor for incident diabetes mellitus among middle-aged men. Results from the MONICA Augsburg Cohort Study, 1984-1998. *Arch Intern Med* 163:93-9
103. Rumley A, Woodward M, Hoffmeister A, Koenig W, Lowe GD (2003). Comparison of plasma fibrinogen by Clauss, prothrombin-time derived, and immunonephelometric assays in a general population: implications for risk stratification by thirds of fibrinogen. *Blood Coagul Fibrinolysis* 14:197-201
104. Marx N, Froehlich J, Siam L, Ittner J, Wierse G, Schmidt A, Hombach V, Koenig W (2003). Antidiabetic PPAR γ -activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease. *Arterioscler Thromb Vasc Biol* 23:283-8
105. Imhof A, Fröhlich M, Löwel H, Helbecque N, Woodward M, Amouyel P, Lowe GDO, Koenig W (2003). Distributions of C-reactive protein, measured by high-sensitivity assays in apparently healthy men and women from three different populations in Europe. *Clin Chem* 49:669-72
106. Imhof A, Koenig W (2003). Atherosklerose als inflammatorischer Prozess. *CARDIOVASC* 3:30-2
107. Marx N, Imhof A, Froehlich J, Siam L, Ittner J, Wierse G, Schmidt A, Hombach V, Koenig W (2003). Effect of rosiglitazone treatment on soluble CD40L in type-2 diabetic patients with coronary artery disease. *Circulation* 107:1954-7
108. Zegura B, Keber I, Sebestjen M, Koenig W (2003). Double-blind, randomized study of estradiol replacement therapy on markers of inflammation, coagulation and fibrinolysis. *Atherosclerosis* 168:123-9

109. Rothenbacher D, Hoffmeister A, Brenner H, Koenig W (2003). Physical activity, coronary heart disease and inflammatory response. A case-control study. *Arch Intern Med* 163:1200-5
110. Woodward M, Lowe G, Rumley A, Imhof A, Koenig W (2003). Measurement of plasma viscosity in stored frozen samples: a general population study. *Blood Coagul Fibrinolysis* 14:417-20
111. Wöhrle J, Nusser T, Hoffmeister A, Kestler HA, Grebe OC, Höher M, Hombach V, Koenig W, Kochs M (2003). Effect of molsidomine on rheological parameters and the incidence of cardiovascular events. *Dtsch Med Wochenschr* 128:1333-7
112. Fröhlich M, Sund M, Löwel H, Imhof A, Hoffmeister A, Koenig W (2003). Independent association of various smoking characteristics with markers of systemic inflammation in men: Results from a representative sample of the general population (MONICA Augsburg Survey 1994/95). *Eur Heart J* 24:1365-72
113. Ladwig KH, Marten-Mittag B, Löwel H, Döring A, Koenig W (2003). Influence of depressive mood on the association of CRP and obesity in 3,025 middle aged healthy men. *Brain Behav Immun* 17:268-75
114. Imhof A, Rothenbacher D, Khuseyinova N, Hoffmeister A, Maerz W, Nauck M, Scharnagl H, Koenig W, Brenner H (2003). Plasma lipoprotein Lp(a), markers of hemostasis and inflammation and risk of coronary heart disease. *J Cardiovasc Risk* 10:362-70
115. Khuseyinova N, Imhof A, Trischler G, Rothenbacher D, Hutchinson WL, Pepys MB, Koenig W (2003). Determination of C-reactive protein: comparison of three high-sensitivity immunoassays. *Clin Chem* 49:1691-5
116. Rothenbacher D, Brenner H, Hoffmeister A, Mertens Th, Persson K, Koenig W (2003). Relationship between infectious burden, systemic inflammatory response, and risk of stable coronary artery disease: role of confounding and reference group. *Atherosclerosis* 170: 339-45
117. Hoffmeister A, Imhof A, Rothenbacher D, Khuseyinova N, Brenner H, Koenig W (2003). Moderate alcohol consumption and plasma concentration of sensitive markers of inflammation. Comment on an atheroprotective relationship. *Dtsch Med Wochenschr* 128:2237-41
118. Illig T, Bongardt F, Schöpfer A, Holle R, Müller S, Rathmann W, Koenig W, Meisinger C, Wichmann HE, Kolb H for the KORA Study Group (2003). The endotoxin receptor TLR4 polymorphism is not associated with diabetes or components of the metabolic syndrome. *Diabetes* 52: 2861-4
119. März W, Koenig W (2003). HMG-CoA reductase inhibition: anti-inflammatory effects beyond lipid lowering? *J Cardiovasc Risk* 10:169-79
120. Manolov DE, Koenig W, Hombach V, Torzewski J (2003). C-reactive protein and atherosclerosis – Is there a causal link? *Histol Histopathol* 18:1189-93

121. Imhof A, Koenig W (2003). Alcohol, inflammation and coronary heart disease. *Addict Biol* 8:271-7
122. Naghavi M, Libby P, Falk E, Casscells W, Litovsky S, Pasterkamp G, Madjid M, Rumberger J, Badimon JJ, Moreno P, Stone PH, Fayad Z, Waxman S, Raggi P, Yuan C, Saloner D, Fitzgerald PJ, Siscovick DS, Stefanadis C, de Korte CL, Zarrabi A, Aikawa M, Airaksinen KEJ, Assmann G, Becker CR, Chesebro JH, Farb A, Galis ZS, Jackson C, Jang IK, Koenig W, Lodder RA, March K, Navab M, Priori SG, Rekhater MD, Bahr R, Grundy SM, Mehran R, Colombo A, Schwartz RS, Serruys PW, Hansson GK, Shah PK, Muller JE, Virmani R, Yusuf S, Roberts R, Zipes DP, Willerson JT (2003). From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies. Part I. *Circulation* 108:1664-72
123. Naghavi M, Libby P, Falk E, Casscells W, Litovsky S, Pasterkamp G, Madjid M, Rumberger J, Badimon JJ, Moreno P, Stone PH, Fayad Z, Waxman S, Raggi P, Yuan C, Saloner D, Fitzgerald PJ, Siscovick DS, Stefanadis C, de Korte CL, Zarrabi A, Aikawa M, Airaksinen KEJ, Assmann G, Becker CR, Chesebro JH, Farb A, Galis ZS, Jackson C, Jang IK, Koenig W, Lodder RA, March K, Navab M, Priori SG, Rekhater MD, Bahr R, Grundy SM, Mehran R, Colombo A, Schwartz RS, Serruys PW, Hansson GK, Shah PK, Muller JE, Virmani R, Yusuf S, Roberts R, Zipes DP, Willerson JT (2003). From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies. Part II. *Circulation* 108:1772-8

2004

124. Koenig W, Loewel H, Baumert J, Meisinger C (2004). C-reactive protein modulates risk prediction based on the Framingham Score – Implications for future risk assessment? *Circulation* 109:1349-53
125. Koenig W, Khuseyinova N, Trischler G, Löwel H, Meisinger C (2004). Lipoprotein-associated phospholipase A₂ adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population. Results from the 14 year follow-up of a large cohort from Southern Germany. *Circulation* 110:1903-8
126. Koenig W (2004). Brauchen wir neue Labormarker für die Diagnostik des akuten Koronarsyndroms? Kommentar. *Dtsch Med Wochenschr* 129:235
127. Koenig W (2004). Nicht nur die bisher bekannten metabolischen Prozesse spielen beim Herzinfarkt eine Rolle. Kommentar. *Dtsch Med Wochenschr* 129:1546
128. Ridker PM, Koenig W, Fuster V (2004). C-reactive protein and coronary heart disease. Letter. *N Engl J Med* 351:295-8
129. Fibrinogen Studies Collaboration. Collaborative meta-analysis of prospective studies of plasma fibrinogen and cardiovascular disease. *Eur J Cardiovasc Prev Rehab* 11 (2004) 9-17

130. Scharnagl H, Busse-Grawitz A, Koenig W, Wieland H, Kist M, März W (2004). *Helicobacter pylori* eradication increases HDL cholesterol. *Am J Cardiol* 93:219-20
131. Hrycaj PZ, Stürmer T, Brenner H, Koenig W, Gunther KP. (2004). Systemic inflammation in osteoarthritis. *Ann Rheum Dis* 63:750-751
132. Döring A, Fröhlich M, Löwel H, Koenig W (2004). Third generation oral contraceptive use and cardiovascular risk factors. *Atherosclerosis* 172:281-6
133. Stürmer T, Brenner H, Koenig W, Günther KP (2004). Severity and extent of osteoarthritis and low grade systemic inflammation as assessed by high-sensitivity C-reactive protein. *Ann Rheum Dis* 63:200-5
134. Gervois P, Kleemann R, Pillon A, Percevault F, Koenig W, Staels B, Kooistra T (2004). Global suppression of IL-6-induced acute phase response gene expression after chronic in vivo treatment with the peroxisome-proliferator-activated receptor-alpha activator fenofibrate. *J Biol Chem* 279:16154-60
135. März W, Nauck M, Hoffmann MM, Nagel D, Boehm BO, Koenig W, Rothenbacher D, Winkelmann BR (2004). The G(-30)A polymorphism in the promoter region of the glucokinase gene is associated with angiographically defined coronary artery disease, type 2 diabetes mellitus and glucose metabolism. *Circulation* 109:2844-9
136. Patsouris D, Mandard S, Voshol PJ, Escher P, Tan NS, Havekes LM, Koenig W, März W, Tafuri S, Wahli W, Müller M, Kersten S (2004). PPAR α governs glycerol metabolism. *J Clin Invest* 114:94-103
137. Mandard S, Zandbergen F, Tan NS, Escher P, Patsouris D, Koenig W, Kleemann R, Bakker A, Veenman F, Wahli W, Müller M, Kersten S (2004). The direct PPAR target FIAF/PGAR/ANGPTL4 is present in blood plasma as a truncated protein that is increased by fenofibrate treatment. *J Biol Chem* 279: 34411-20
138. Fütth R, Herder C, Förster S, Müller-Scholze S, Kruse N, Rieckmann P, Heinig A, Koenig W, Scherbaum WA, Kolb H, Martin S (2004). Evaluation of diagnostic relevance of mRNA levels in peripheral blood: predictive value for mortality in hemodialysis patients. *Cytokine* 27:166-72
139. Illig T, Bongardt F, Schöpfer A, Müller-Scholze S, Rathmann W, Koenig W, Thorand B, Vollmert C, Holle R, Kolb H, Herder C (2004). Significant association of the interleukin-6 gene polymorphisms C-174G and A-598G with type 2 diabetes. *J Clin Endocrinol Metab* 89:5053-8
140. Imhof A, Fröhlich M, Doering A, Thorand B, Amouyel Ph, Helbeque N, Lowe GDO, Woodward M, Koenig W (2004). Overall alcohol intake, beer, wine, and systemic markers of inflammation in western Europe: results from three MONICA samplers (Augsburg, Glasgow, Lille). *Eur Heart J* 25;2092-2100
141. Smith SC, Anderson JL, Cannon RO, Fadhil YY, Koenig W, Libby P, Lipshultz SE, Mensah GA, Ridker PM, Rosenson R (2004). CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease. Application to Clinical

and Public Health Practice. Report from the Clinical Practice Discussion Group. *Circulation* 110:e550-3

142. Chapman MJ, Assmann G, Fruchart JC, Sirtori C on behalf of the European Consensus Panel on HDL-C (2004). Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid – a position paper developed by the European Consensus Panel on HDL-C. *Curr Med Res Opin* 20;1253-8

2005

143. Koenig W, Twardella D, Brenner H, Rothenbacher D (2005). Cystatin C levels in patients with coronary heart disease and risk for recurrent cardiovascular events: More than simply a marker of glomerular filtration rate. *Clin Chem* 51:321-7
144. Koenig W (2005). Predicting risk and treatment benefit in atherosclerosis: the role of C-reactive protein. *Int J Cardiol* 98:199-206
145. Koenig W, Meisinger C, Baumert J, Khuseyinova N, Lowel H (2005). Systemic low-grade inflammation and risk of coronary heart disease: results from the MONICA/KORA Augsburg cohort studies. *Gesundheitswesen* 67 Suppl 1:S62-7.
146. Koenig W (2005). Biomarkers for mortality and cardiovascular events. Letter to the editor. *JAMA* 294:303-4.
147. Koenig W. (2005). Wer die Wahl hat hat die Qual: Immer mehr Biomarker zur Risikostratifizierung. *Kommentar. Dtsch Med Wochenschr* 130:1420
148. Hoffmeister A, Rothenbacher D, Kunze M, Brenner H, Koenig W (2005). Prognostic value of sensitive markers of inflammation alone and in combination with lipid markers in patients with stable coronary heart disease. *Eur J Int Med* 16:47-52
149. Meisinger C, Loewel H, Mraz W, Koenig W (2005). Prognostic value of apolipoprotein B and A-I in the prediction of myocardial infarction in middle-aged men and women. Results from the MONICA/KORA Augsburg Cohort Study. *Eur Heart J* 26:271-8
150. Mostafazadeh A, Herder C, Haastert B, Hanifi-Moghaddam P, Schloot N, Koenig W, Illig Th, Thorand B, Holle R, Eslami MB, Kolb H, for the KORA Group (2005). Association of humoral immunity to human Hsp60 with the IL-6 gene polymorphism C-174G in patients with type 2 diabetes and controls. *Hormone Metab Res* 37:257-63
151. Rothenbacher D, Brenner H, Mertens T, Hoffmann MM, Hoffmeister A, Koenig W (2005). Prognostic value of interleukin-1 receptor antagonist gene polymorphism and cytomegalovirus seroprevalence in patients with coronary artery disease. *BMC Cardiovascular Disorders* 5:10

152. Zumkeller N, Koenig W, Hoffmann MM, Kolb H, Brenner H, Rothenbacher D (2005). *Helicobacter pylori* seropositive subjects do not show a pronounced systemic inflammatory response even in the presence of the interleukin-1 receptor antagonist gene polymorphism. *Epidemiol Infect* 133:569-72
153. Loew M, Hoffmann MM, Koenig W, Brenner H, Rothenbacher D (2005). Genotype and plasma concentration of Cystatin C in patients with coronary heart disease and risk for secondary cardiovascular events. *Arterioscler Thromb Vasc Biol* 25:1470-4
154. Rothenbacher D, Brenner H, März W, Koenig W (2005). Adiponectin, risk of coronary heart disease and correlations with cardiovascular risk markers. *Eur Heart J* 26:1640-6
155. Meisinger C, Baumert J, Khuseyinova N, Löwel H, Koenig W (2005). Plasma oxidized low-density lipoprotein: A strong predictor for acute coronary heart disease events in apparently healthy middle-aged men from Southern Germany. *Circulation* 112:651-7
156. Khuseyinova N, Imhof A, Rothenbacher D, Trischler G, Kuelb S, Scharnagl H, März W, Brenner H, Koenig W (2005). Association between Lp-PLA₂ and coronary artery disease: Focus on its relationship with lipoproteins and markers of inflammation and hemostasis. *Atherosclerosis* 182:181-8
157. Hetzel J, Balletshofer B, Rittig K, Walcher D, Kratzer W, Hombach V, Häring U, Koenig W, Marx N (2005). Rapid effect of rosiglitazone treatment on endothelial function and inflammatory biomarkers. *Arterioscler Thromb Vasc Biol* 25:1804-9
158. Thorand B, Kolb H, Baumert J, Koenig W, Chambless L, Meisinger C, Illig T, Martin S, Herder C (2005). Elevated levels of interleukin 18 predict the development of type 2 diabetes mellitus. Results from the MONICA/KORA Augsburg studies 1984-2002. *Diabetes* 54:2932-8
159. Fibrinogen Studies Collaboration (2005). Plasma fibrinogen levels and the risk of major cardiovascular diseases and non-vascular mortality: An individual participant meta-analysis. *JAMA* 294:1799-809
160. Marx N, Woehrle J, Nusser T, Walcher D, Rinker A, Hombach V, Koenig W, Höher M (2005). Pioglitazone reduces neointimal proliferation after coronary stent implantation: a randomized, placebo-controlled, double-blind trial in non-diabetic patients. *Circulation* 112:2792-8
161. Walcher T, Haenle MM, Kron M, Hay B, Mason RA, von Schmiesing AF, Imhof A, Koenig W, Kern P, Boehm BO, Kratzer W (2005). Pregnancy is not a risk factor for gallstone disease: results of a randomly selected population sample. *World J Gastroenterol* 11:6800-6
162. Ladwig KH, Marten-Mittag B, Löwel H, Döring A, Koenig W (2005). Depressive mood, C-reactive protein and the prediction of coronary heart disease in initially healthy men. Results from the MONICA -KORA Augsburg Cohort Study 1984-1998. *Eur Heart J* 26:2537-42

163. Schulz H, Harder V, Ibald-Mulli A, Khandoga A, Koenig W, Krombach F, Radykewicz R, Stampfl A, Thorand B, Peters A (2005). Cardiovascular effects of fine and ultrafine particles. *J Aerosol Med* 18:1-22
164. Rathmann W, Haastert B, Giani G, Holle R, Koenig W, Herder C, Löwel H (2005). Critical evaluation of models to identify individuals with insulin resistance. Letter to the editor. *Diabetes Care* 28:1833
165. Boehm BO, Claudi-Boehm S, Yilidrim S, Haenle MM, Hay B, Mason RA, Steinbach G, Koenig W, Kern P, März W, Kratzer W for the Römerstein and the EMIL-Study Group (2005). Prevalence of the metabolic syndrome in Southwest Germany. *Scand J Clin Lab Invest* 65 (Suppl 240):122-8
166. Lepper PM, Koenig W, Möller P, Perner S (2005). A case of sudden cardiac death due to isolated eosinophilic coronary arteritis. *Chest* 128:1047-50
167. Herder C, Haastert B, Muller-Scholze S, Koenig W, Thorand B, Holle R, Wichmann HE, Scherbaum WA, Martin S, Kolb H (2005). Association of Systemic Chemokine Concentrations With Impaired Glucose Tolerance and Type 2 Diabetes: Results from the Cooperative Health Research in the Region of Augsburg Survey S4 (KORA S4). *Diabetes* 54(Suppl 2):S11-7
168. Illig T, Bongardt F, Schopfer-Wendels A, Huth C, Heid I, Rathmann W, Martin S, Vollmert C, Holle R, Thorand B, Wichmann HE, Koenig W, Kolb H, Herder C; KORA Study Group (2005). Genetics of type 2 diabetes: impact of interleukin-6 gene variants. *Gesundheitswesen* 67 (Suppl 1):S122-6
169. Herder C, Illig T, Rathmann W, Martin S, Haastert B, Muller-Scholze S, Holle R, Thorand B, Koenig W, Wichmann HE, Kolb H; KORA Study Group (2005). Inflammation and type 2 diabetes: results from KORA Augsburg. *Gesundheitswesen* 67(Suppl 1):S115-21

2006

170. Koenig W, Khuseyinova N, Baumert J, Meisinger C, Lowel H (2006). Serum concentrations of adiponectin and risk of type 2 diabetes mellitus and coronary heart disease in apparently healthy middle-aged men: results from the 18-year follow-up of a large cohort from southern Germany. *J Am Coll Cardiol* 48:1369-77.
171. Koenig W, Twardella D, Brenner H, Rothenbacher D (2006). Lipoprotein-associated phospholipase A2 predicts future cardiovascular events in patients with coronary heart disease independently of traditional risk factors, markers of inflammation, renal function, and hemodynamic stress. *Arterioscler Thromb Vasc Biol* 26:1586-93.
172. Koenig W, Khuseyinova N, Baumert J, Thorand B, Loewel H, Chambless L, Meisinger C, Schneider A, Martin S, Kolb H, Herder C (2006). Increased concentrations of C-reactive protein and IL-6 but not IL-18 are independently associated with incident coronary events in middle-aged men

- and women: results from the MONICA/KORA Augsburg case-cohort study, 1984-2002. *Arterioscler Thromb Vasc Biol* 26:2745-51.
173. Kooistra T, Verschuren L, de Vries-van der Weij J, Koenig W, Toet K, Princen HM, Kleemann R (2006). Fenofibrate reduces atherogenesis in ApoE*3Leiden mice: evidence for multiple antiatherogenic effects besides lowering plasma cholesterol. *Arterioscler Thromb Vasc Biol* 26:2322-30.
 174. Lamina C, Meisinger C, Heid IM, Lowel H, Rantner B, Koenig W, Kronenberg F; Kora Study Group (2006). Association of ankle-brachial index and plaques in the carotid and femoral arteries with cardiovascular events and total mortality in a population-based study with 13 years of follow-up. *Eur Heart J* 27:2580-7.
 175. Thorand B, Baumert J, Döring A, Herder C, Kolb H, Rathmann W, Giani G, Koenig W for the KORA Study Group (2006). Sex differences in the relation of body composition to markers of inflammation. Results from the KORA Augsburg Survey 2000. *Atherosclerosis* 184:216-24
 176. Thorand B, Baumert J, Schneider A, Chambless L, Löwel H, Kolb H, Koenig W. for the KORA Study Group (2006). Association of cardiovascular risk factors with markers of endothelial dysfunction in middle-aged men and women – Results from the MONICA/KORA Augsburg Study. *Thromb Haemost* 95:134-41
 177. Thorand B, Baumert J, Chambless L, Meisinger C, Kolb H, Döring A, Löwel H, Koenig W (2006). Elevated markers of endothelial dysfunction predict incident type 2 diabetes mellitus in middle-aged men and women. Results from the MONICA/KORA Augsburg Study, 1984-2002. *Arterioscler Thromb Vasc Biol* 26:398-405
 178. Meisner F, Walcher D, Gizard F, Kapfer X, Huber R, Noak A, Sunder-Plassmann L, Bach H, Haug C, Bachem M, Stojakovic T, Marz W, Hombach V, Koenig W, Staels B, Marx N (2006). Effect of rosiglitazone treatment on plaque inflammation and collagen content in nondiabetic patients: data from a randomized placebo-controlled trial. *Arterioscler Thromb Vasc Biol* 26:845-50.
 179. Naghavi M, Falk E, Hecht HS, Jamieson MJ, Kaul S, Berman D, Fayad Z, Budoff MJ, Rumberger J, Naqvi TZ, Shaw LJ, Faergeman O, Cohn J, Bahr R, Koenig W, Demirovic J, Arking D, Herrera VL, Badimon J, Goldstein JA, Rudy Y, Airaksinen J, Schwartz RS, Riley WA, Mendes RA, Douglas P, Shah PK (2006). SHAPE Task Force. From vulnerable plaque to vulnerable patient--Part III: Executive summary of the Screening for Heart Attack Prevention and Education (SHAPE) Task Force report. *Am J Cardiol* 98(2A):2H-15H.
 180. Herder C, Peltonen M, Koenig W, Kraft I, Muller-Scholze S, Martin S, Lakka T, Ilanne-Parikka P, Eriksson JG, Hamalainen H, Keinanen-Kiukaanniemi S, Valle TT, Uusitupa M, Lindstrom J, Kolb H, Tuomilehto J (2006). Systemic immune mediators and lifestyle changes in the prevention of type 2

diabetes: results from the Finnish Diabetes Prevention Study. *Diabetes* 55:2340-6.

181. Herder C, Haastert B, Müller-Scholze S, Koenig W, Thorand B, Holle R, Wichmann HE, Scherbaum WA, Martin S, Kolb H (2006). Association of systemic chemokine concentrations with impaired glucose tolerance and type 2 diabetes – Results from the KORA Survey 2000. *Diabetes* 54 (Suppl 2):s11-7
182. Herder C, Müller-Scholze S, Rating P, Koenig W, Thorand B, Haastert B, Holle R, Illig T, Rathmann W, Seissler J, Wichmann HE, Kolb H (2006). Systemic monocyte chemoattractant protein-1 concentrations are independent of type 2 diabetes mellitus or parameters of obesity: Results from the Cooperative Research in the Region of Augsburg Survey S 4 (KORA S 4). *Eur J Endocrinol* 154:311-7
183. Herder C, Kolb H, Koenig W, Haastert B, Müller-Scholze S, Rathmann W, Holle R, Thorand B, Wichmann HE (2006). Association of systemic concentrations of macrophage migration inhibitory factor with impaired glucose tolerance and type 2 diabetes: Results from the KORA Survey 2000. *Diabetes Care* 29:368-71
184. Herder C, Baumert J, Kolb H, Koenig W, Martin S, Thorand B (2006). Circulating IL-18 concentration independent of body fat and fat-free mass – Results from the MONICA/KORA Augsburg Study. *Diabetes Care* 29:174-5
185. Herder C, Baumert J, Thorand B, Koenig W, de Jager W, Meisinger C, Illig T, Martin S, Kolb H (2006). Chemokines as risk factors for type 2 diabetes: results from the MONICA/KORA Augsburg study, 1984-2002. *Diabetologia* 49:921-9
186. Herder C, Hauner H, Haastert B, Rohrig K, Koenig W, Kolb H, Müller-Scholze S, Thorand B, Holle R, Rathmann W (2006). Hypoadiponectinemia and proinflammatory state: two sides of the same coin: results from the Cooperative Health Research in the Region of Augsburg Survey 4 (KORA S4). *Diabetes Care* 29:1626-31
187. Herder C, Baumert J, Thorand B, Martin S, Lowel H, Kolb H, Koenig W. Chemokines and incident coronary heart disease: results from the MONICA/KORA Augsburg case-cohort study, 1984-2002. *Arterioscler Thromb Vasc Biol* 2006;26:2147-52.
188. Haenle MM, Brockmann SO, Kron M, Bertling U, Mason RA, Steinbach G, Boehm BO, Koenig W, Kern P, Piechotowski I, Kratzer W; EMIL-Study group (2006). Overweight, physical activity, tobacco and alcohol consumption in a cross-sectional random sample of German adults. *BMC Public Health* 6:233.
189. Khuseyinova N, Koenig W (2006). Apolipoprotein A-I and risk for cardiovascular diseases. *Curr Atheroscler Rep* 8:365-73.

190. Khuseyinova N, Koenig W (2006). Biomarkers of outcome from cardiovascular disease. *Curr Opin Crit Care* 12:412-9.
191. Rathmann W, Giani G, Koenig W, Imhof A, Kolb H, Löwel H, Holle R, Mielck A (2006). Is inflammation a causal chain between low socioeconomic status and type 2 diabetes mellitus. Results from the KORA Survey 2000. *Eur J Epidemiol* 21:55-60.
192. Rathmann W, Haastert B, Icks A, Giani G, Holle R, Koenig W, Kolb H, Löwel H, Meisinger C (2006). Prevalence of the Metabolic Syndrome in the Elderly Population According to IDF, WHO, and NCEP Definitions and Associations With C-Reactive Protein: The KORA Survey 2000. *Diabetes Care*, 29:461 Letters: Observations
193. Rathmann W, Haastert B, Icks A, Giani G, Holle R, Koenig W, Kolb H, Löwel H, Meisinger C (2006). Prevalence of the metabolic syndrome in the elderly population according to IDF, WHO, and NCEP definitions and associations with C-reactive protein: The KORA Survey 2000. *Diabetes Care* 29:461
194. Ridker P, Rifai N, Koenig W, Blumenthal RS (2006). C-reactive protein and cardiovascular risk in the Framingham Study. *Arch Intern Med* 166:1327-8
195. Rothenbacher D, Müller-Scholze S, Herder C, Koenig W, Kolb H (2006). Differential Expression of Chemokines, Risk of Stable Coronary Heart Disease, and Correlation with Established Cardiovascular Risk Markers. *Arterioscler Thromb Vasc Biol* 26:194-9.
196. Rothenbacher D, Koenig W, Brenner H (2006). Comparison of N-terminal pro-B-natriuretic peptide, C-reactive protein, and creatinine clearance for prognosis in patients with known coronary heart disease. *Arch Intern Med* 166:2455-60.
197. Rothenbacher D, Koenig W, Brenner H (2006). Lifetime physical activity patterns and risk of coronary heart disease. *Heart* 92:1319-20.
198. Ruckerl R, Ibal-Mulli A, Koenig W, Henneberger A, Woelke G, Cyrus J, Heinrich J, Marder V, Frampton M, Wichmann HE, Peters A (2006). Ambient air pollution and markers of inflammation and coagulation in patients with coronary heart disease. Air pollution and markers of inflammation and coagulation in patients with coronary heart disease. *Am J Respir Crit Care Med* 173:432-41
199. Spahr A, Klein E, Khuseyinova N, Boeckh C, Pezeshki G, Muche R, Kunze M, Rothenbacher D, Hoffmeister A, Koenig W (2006). Periodontal infections and coronary heart disease: Role of periodontal bacteria and importance of total pathogen burden. The *Coronary Event and Periodontal Disease (CORODONT)* Study. *Arch Intern Med* 166:554-9

2007

200. Maas R, Schulze F, Baumert J, Lowel H, Hamraz K, Schwedhelm E, Koenig W, Boger RH (2007). Asymmetric dimethylarginine, smoking, and risk of coronary heart disease in apparently healthy men: prospective analysis from the population-based Monitoring of Trends and Determinants in Cardiovascular Disease/Kooperative Gesundheitsforschung in der Region Augsburg study and experimental data. *Clin Chem* 53:693-701
201. Thorand B, Baumert J, Kolb H, Meisinger C, Chambless L, Koenig W, Herder C (2007). Sex differences in the prediction of type 2 diabetes by inflammatory markers: results from the MONICA/KORA Augsburg case-cohort study, 1984-2002. *Diabetes Care* 30:854-60
202. Koenig W, Khuseyinova N (2007). Biomarkers of atherosclerotic plaque instability and rupture. *ATVB* 27:15-26
203. Koenig W (2007). Is elevated cystatin C a predictor of cardiovascular risk in elderly people without chronic kidney disease? *Nat Clin Pract Cardiovasc Med* 4: 76-77.
204. Koenig W. Serum amyloid P component and cardiovascular disease: is there a sensible link? (2007) Editorial. *Arterioscler Thromb Vasc Biol* 27:698-700
205. Koenig W (2007). Cardiovascular biomarkers: added value using an integrated approach? Editorial. *Circulation* 116:3-5
206. Marcovina SM, Crea F, Davignon J, Kaski JC, Koenig W, Landmesser U, Pieri PL, Schulz-Menger J, Shaw LJ, Sobesky J (2007). Biochemical and bioimaging markers for risk assessment and diagnosis in major cardiovascular diseases: a road to integration of complementary diagnostic tools. *J Intern Med* 261:214-234.
207. The Lp-PLA2 Studies Collaboration, Ballantyne C, Cushman M, Psaty B, Furberg C, Khaw KT, Sandhu M, Oldgren J, Rossi GP, Maiolino G, Cesari M, Lenzini L, James SK, Rimm E, Collins R, Anderson J, Koenig W, Brenner H, Rothenbacher D, Berglund G, Persson M, Berger P, Brilakis E, McConnell JP, Koenig W, Sacco R, Elkind M, Talmud P, Rimm E, Cannon CP, Packard C, Barrett-Connor E, Hofman A, Kardys I, Witteman JC, Criqui M, Corsetti JP, Rainwater DL, Moss AJ, Robins S, Bloomfield H, Collins D, Packard C, Wassertheil-Smoller S, Ridker P, Ballantyne C, Cannon CP, Cushman M, Danesh J, Gu D, Hofman A, Nelson JJ, Thompson S, Zalewski A, Zariffa N, Di Angelantonio E, Kaptoge S, Thompson A, Thompson S, Walker M, Watson S, Wood A (2007). Collaborative meta-analysis of individual participant data from observational studies of Lp-PLA2 and cardiovascular diseases. *Eur J Cardiovasc Prev Rehabil* 14:3-11
208. Thorand B, Baumert J, Herder C, Meisinger C, Koenig W (2007). Soluble thrombomodulin as a predictor of type 2 diabetes: results from the MONICA/KORA Augsburg case-cohort study, 1984-1998. *Diabetologia* 50:545-8.
209. Rathmann W, Haastert B, Herder C, Hauner H, Koenig W, Meisinger C, Holle R, Giani G (2007). Differential association of adiponectin with cardiovascular

risk markers in men and women? The KORA survey 2000. *Int J Obes (Lond)* 31:770-6

210. Yue W, Schneider A, Ruckerl R, Koenig W, Marder V, Wang S, Wichmann HE, Peters A, Zareba W (2007). Relationship between electrocardiographic and biochemical variables in coronary artery disease. *Int J Cardiol* 119:185-91.
211. Schmidt EB, Koenig W, Khuseyinova N, Christensen JH (2007). Lipoprotein-associated phospholipase A₂ concentrations in plasma are associated with the extent of coronary artery disease and correlate to adipose tissue levels of marine n-3 fatty acids. *Atherosclerosis* [Epub ahead of print; Dec 7]
212. Scheurig AC, Thorand B, Fischer B, Heier M, Koenig W (2007). Association between the intake of vitamins and trace elements from supplements and C-reactive protein: results of the MONICA/KORA Augsburg study. *Eur J Clin Nutr* [Epub ahead of print; Feb 21]
213. Mockel M, Muller R, Vollert JO, Muller C, Danne O, Gareis R, Stork T, Dietz R, Koenig W (2007). Lipoprotein-associated phospholipase A(2) for early risk stratification in patients with suspected acute coronary syndrome: a multi-marker approach : The North Wuerttemberg and Berlin Infarction Study-II (NOBIS-II). *Clin Res Cardiol* [Epub ahead of print; Jun 27]